FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment. This story matters for Finance & Markets readers tracking broker. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BrokerNews curates and briefs the finance & markets stories that matter. Our editorial policy →